Fatal interstitial lung disease associated with Crizotinib pathologically confirmed by percutaneous lung biopsy in a patient with ROS1-rearranged advanced non-small-cell lung cancer: a case report

BACKGROUND: Crizotinib is a multi-target inhibitor approved for the treatment of advanced non-small-cell lung cancer patients with a ROS1 rearrangement. However, interstitial lung disease is a rare but severe and fatal side effect of crizotinib that should lead to immediate discontinuation of the dr...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Shibo, Liu, Kaitai, Ren, Feng, Zheng, Dawei, Pan, Deng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6053720/
https://www.ncbi.nlm.nih.gov/pubmed/30029601
http://dx.doi.org/10.1186/s12890-018-0682-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6053720/
https://www.ncbi.nlm.nih.gov/pubmed/30029601
http://dx.doi.org/10.1186/s12890-018-0682-9

Ejemplares similares